Human Rabies Immunoglobulin

Description

This page contains brief details about the drug human rabies immunoglobulin, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Human Rabies Immunoglobulin Injection (HRIG) contains Human Rabies Immunoglobulin as an active agent. It is indicated to prevent passive, transient rabies infection after exposure to a rabid animal (dogs, mongooses, jackals, foxes). This injection is formulated from blood plasma from screened donors. Rabies infection spreads when a person is bitten, scratched, or licked by an infected animal, especially when the skin is already injured. Though this infection is 100% fatal, it is 100% preventable with timely measures and the correct use of available vaccines, immunoglobulins, or monoclonal antibodies. The first hepatitis B vaccine was approved by the US Food and Drug Administration (FDA) on December 22, 1999, for post-exposure prophylaxis against rabies.

Mechanism of Action of Human Rabies Immunoglobulin

The therapeutic effect of Human Rabies Immunoglobulin is to prevent or treat rabies infection. It works by providing immediate, passive immunity to the rabies virus by neutralizing the virus before it can infect the body’s cells and cause disease. It is usually given along with the rabies vaccine, which helps the body develop its own antibodies against the virus.

Uses of Human Rabies Immunoglobulin

Hepatitis B Vaccine is used to Prevention of rabies infection post-exposure to a rabid animal.

Human Rabies Immunoglobulin Dosage available

Human Rabies Immunoglobulin is administered as an injection, usually by a healthcare professional. The injection is typically given into the muscle or at the site of the bite wound.